Daré Bioscience, Inc. DARE
Set alert
At close · Oct 30
After hours · Oct 30, 7:24 PM ET
- YTD
- -63.75%
- 1 year
- -63.75%
- Open
- 0.7026
- Prev close
- 0.6815
- Mkt cap
- 13.76M
- Vol
- 654.01K
- Avg vol
- 496.64K
- EPS
- -0.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.67
- High
- 0.7026
- Forward P/E
- -2.35
- Beta
- 1.34
- Short ratio
- 0.64
- Inst. own
- 7.59%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.53
- 200-d avg
- 4.07
- 1y target
- 21.33
6M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 1 day ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| RSI: Oversold | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| RSI: Oversold | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 27.75M
- Enterprise value
- 16.85M
- Trailing P/E
- 0.00
- Forward P/E
- -2.35
- PEG ratio
- 0.00
- Price / sales
- 9.77
- Price / book
- 0.00
- EPS (TTM)
- -0.58
- Beta
- 1.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -253.60%
- Revenue (TTM)
- 2.84M
- Revenue growth
- 0.00%
- Free cash flow
- -20.98M
- Total cash
- 16.41M
- Total debt
- 5.83M
- Return on equity
- 0.00%
- Shares outstanding
- 8.70M
- Short % of float
- 0.35%
- 50-day average
- 3.53
- 200-day average
- 4.07
Analyst view
Consensus: buy
- Target (low)
- 12.00
- Target (mean)
- 21.33
- Target (high)
- 39.00
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.63333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.60 | -0.55 | +0.05 | +8.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.57 | 1.52 | +2.09 | +366.67% |
| May 14, 2024 | Mar 1, 2024 | -0.72 | -0.84 | -0.12 | -16.67% |
| Mar 28, 2024 | Dec 1, 2023 | -1.44 | -0.72 | +0.72 | +50.00% |
| Nov 9, 2023 | Sep 1, 2023 | -1.20 | -1.08 | +0.12 | +10.00% |
| Aug 10, 2023 | Jun 1, 2023 | -1.20 | -1.20 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | Jones Trading | main | Buy | Buy |
| Aug 14, 2024 | Maxim Group | down | Buy | Hold |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Daré Bioscience, Inc.
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- darebioscience.com
News
- Daré Bioscience Receive Additional $1.5M Funding Installment Under Grant Agreement For DARE-LARC1
- Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
- Daré Bioscience Addresses New National Focus on Women's Health in Virtual Investor “What This Means” Discussion
- Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
- Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
- Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities
- Contrasting RYTHM (NASDAQ:RYM) & Dare Bioscience (NASDAQ:DARE)
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11
- Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies
Your note
Sign in to keep a note on DARE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.31% | 287,725 | 917.84K | Sep 29, 2024 |
| AMH Equity Ltd. | 1.15% | 100,000 | 319.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 89,060 | 284.10K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.74% | 64,395 | 205.42K | Sep 29, 2024 |
| State Street Corporation | 0.27% | 23,515 | 75.01K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.20% | 17,486 | 55.78K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 205,801 | 656.50K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.91% | 78,984 | 251.96K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 48,543 | 154.85K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 15,461 | 49.32K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 11,774 | 37.56K | Oct 30, 2024 |
| Price (T.Rowe) U.S. Equities Trust | 0.12% | 10,491 | 33.47K | Sep 29, 2024 |